Please click on the link just before the start of the webinar
Hepatitis C virus (HCV) infection is a global public health problem. In this talk, Dr Yousafazi will discuss his key findings on HCV cascades of care, HCV elimination goals, the effect of direct-acting antiviral therapy, and how he hopes to target treatment to reduce vulnerabilities among females, those born overseas, and the Aboriginal population.
 |
Dr M. Tahir Yousafzai Tahir Yousafzai is an assistant professor and infectious disease epidemiologist at the Aga Khan University in Pakistan. He has recently submitted his PhD thesis under the supervision of Professor Gregory Dore at Kirby Institute, UNSW Sydney. Tahir has more than 10 years of global health research experience in Pakistan, Qatar and Australia. He has published more than 90 papers, including first author papers in Lancet Global Health and Lancet Infectious Diseases. His research interests range from surveillance of vaccine preventable diseases, viral hepatitis, impact evaluation of vaccines and vaccine hesitancy. Twitter: @TahirYousafzai8 |
Opinions expressed by individuals at this event are solely of those of the individual/s and do not necessarily represent the views or opinions of the Kirby Institute or UNSW.